The Claim
In patients with heart failure with reduced ejection fraction and type 2 diabetes or prediabetes, empagliflozin reduces epicardial adipose tissue volume, and this reduction is not influenced by baseline epicardial fat volume.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with heart failure and type 2 diabetes or prediabetes, empagliflozin reduces the amount of fat around the heart, and this reduction occurs regardless of how much fat was present before treatment.
See the scientific wording
In patients with heart failure with reduced ejection fraction and type 2 diabetes or prediabetes, the reduction in epicardial adipose tissue volume induced by empagliflozin is not modified by baseline levels of epicardial fat volume, suggesting that the effect of the drug on pericardial fat is consistent regardless of initial fat burden.
Empagliflozin causes the body to burn more fat for energy, which reduces the amount of fat stored around the heart, no matter how much fat was there to start with.
What the research says
1 studyEmpagliflozin reduced heart fat in people with heart failure and diabetes, no matter how much heart fat they started with — meaning it works just as well whether you had a lot or a little fat to begin with.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.